According
to the recently published report 'Probable ATP Dependent RNA Helicase DDX58 -
Pipeline Review, H1 2018'; Probable ATP Dependent RNA Helicase DDX58 (DEAD Box
Protein 58 or RIG I like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein
or DDX58 or EC 3.6.4.13) pipeline Target constitutes close to 10 molecules.
Probable
ATP Dependent RNA Helicase DDX58
(DEAD Box Protein 58 or RIG I like Receptor 1 or Retinoic Acid Inducible Gene 1
Protein or DDX58 or EC 3.6.4.13) - RIG-I (retinoic acid-inducible gene 1) is a
RIG-I-like receptor dsRNA helicase enzyme encoded by the DDX58 gene. It is
involved in viral double-stranded (ds) RNA recognition and the regulation of
immune response. It acts as a cytoplasmic sensor of viral nucleic acids and
plays a major role in sensing viral infection and in the activation of a
cascade of antiviral responses including the induction of type I interferons
and proinflammatory cytokines.
The
report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2018'
outlays comprehensive information on the Probable ATP Dependent RNA Helicase
DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible
Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics, complete with
analysis by indications, stage of development, mechanism of action (MoA), route
of administration (RoA) and molecule type; that are being developed by
Companies / Universities.
It
also reviews key players involved in Probable ATP Dependent RNA Helicase DDX58
(DEAD Box Protein 58 or RIG I like Receptor 1 or Retinoic Acid Inducible Gene 1
Protein or DDX58 or EC 3.6.4.13) targeted therapeutics development with
respective active and dormant or discontinued projects. Currently, The
molecules developed by companies in Phase II, Phase I and Preclinical stages
are 3, 1 and 6 respectively.
Report
covers products from therapy areas Infectious Disease and Oncology which
include indications Hepatitis B, Viral Infections, Solid Tumor, Human
Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Lymphoma and
Multiple Myeloma (Kahler Disease).
The
report provides a snapshot of the global therapeutic landscape for Probable ATP
Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I like Receptor 1 or
Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)
The
report reviews Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58
or RIG I like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or
EC 3.6.4.13) targeted therapeutics under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources
The
report covers pipeline products based on various stages of development ranging
from pre-registration till discovery and undisclosed stages
The
report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
The
report reviews key players involved in Probable ATP Dependent RNA Helicase
DDX58 (DEAD Box Protein 58 or RIG I like Receptor 1 or Retinoic Acid Inducible
Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics and enlists all
their major and minor projects
The
report assesses Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58
or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or
EC 3.6.4.13) targeted therapeutics based on mechanism of action (MoA), route of
administration (RoA) and molecule type
The
report summarizes all the dormant and discontinued pipeline projects
The
report reviews latest news and deals related to Probable ATP Dependent RNA
Helicase DDX58 (DEAD Box Protein 58 or RIG I like Receptor 1 or Retinoic Acid
Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics
To know more, click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204